**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO.:** 25314

**Column:** **ORIGINAL ARTICLE**

***Case Control Study***

**Relationships** **between cell cycle pathway genes polymorphisms and the risk of hepatocellular carcinoma**

Nan YL *et al*. Cell cycle pathway genes polymorphisms and HCC

Yue-Li Nan, Yan-Ling Hu, Zhi-Ke Liu, Fang-Fang Duan, Yang Xu, Shu Li, Ting Li, Da-Fang Chen, Xiao-Yun Zeng

**Yue-Li Nan, Yang Xu, Shu Li, Ting Li, Xiao-Yun Zeng,** Department of Epidemiology, School of Public Health, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Yan-Ling Hu,** Medical Scientific Research Centre, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Zhi-Ke Liu, Fang-Fang Duan,** **Da-Fang Chen,** Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100191, China

**Xiao-Yun Zeng,** Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Author contributions:**Zeng XY designed the research; Xu Y, Li S, and Li T collected material and clinical data; Liu ZK and Duan FF performed the majority of experiments; Chen DF conceived the experimental assays; Nan YL performed the experiments, analyzed the data and wrote the manuscript; Hu YL made critical revisions of the manuscript.

**Supported by** National Natural Science Foundation of China, No. 81360448; Natural Science Foundation of Guangxi, No. 2014GXNSFAA118139; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, No. GK2015-ZZ03 and No. GK2014-ZZ03; and Guangxi Outstanding Teachers Training Project for Colleges.

**Institutional review board statement:** The study was approved by the ethical review committee of Guangxi Medical University.

**Informed consent statement**: All study participants provided informed written consent prior to study enrollment.

**Conflict-of-interest statement**: The authors have declared that they have no competing interests.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:****Xiao-Yun Zeng, MD, PhD,** School of Public Health, Guangxi Medical University, No. 22 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. [zxyxjw@21cn.com](mailto:zxyxjw@21cn.com)

**Telephone:** +86-13517812296

**Fax:** +86-0771-5352523

**Received:** March 3, 2016

**Peer–review started:** March 7, 2016

**Frist decision:** April 14, 2016

**Revised:** April 29, 2016

**Accepted:** May 21, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigate associations between the polymorphisms of cell cycle pathway genes and the risk of hepatocellular carcinoma (HCC).

**METHODS**: We enrolled 1127 cases newly diagnosed with HCC from the Tumor Hospital of Guangxi Medical University and 1200 non-tumor patients from the First Affiliated Hospital of Guangxi Medical University. General demographic characteristics, behavioral information, and hematological indices were collected by unified questionnaires. Genomic DNA was isolated from peripheral venous blood using Phenol-Chloroform. The genotyping was performed using the Sequenom MassARRAY iPLEX genotyping method. The association between genetic polymorphisms and risk of HCC was shown by *P* value and the odd ratio (OR) with 95% confidence interval (CI) using the unconditional logistic regression after adjusting for age, sex, nationality, smoking, drinking, family history of HCC, and hepatitis B virus (HBV) infection. Moreover, stratified analysis was conducted on the basis of the status of HBV infection, smoking, drinking alcohol.

**RESULTS**: The HCC risk was lower in patients with the *MCM4* rs2305952 CC (OR = 0.22, 95%CI: 0.08–0.63, *P* = 0.01) and with the *CHEK1* rs515255 TC, TT, TC/TT (OR = 0.73, 95%CI: 0.56–0.96, *P* = 0.02; OR = 0.67, 95%CI: 0.46–0.97, *P* = 0.04; OR = 0.72, 95%CI: 0.56–0.92, *P* = 0.01, respectively). Conversely, the HCC risk was higher in patients with the *KAT2B* rs17006625 GG (OR = 1.64, 95%CI: 1.01–2.64, *P* = 0.04). In addition, the risk were markedly lower for those who were carriers *MCM4* rs2305952 CC and were also HBsAg-positive and non-drinking and non-smoking (*P <* 0.05, respectively) and for those who were carriers *CHEK1* rs515255 TC, TT, TC/TT and were also HBsAg-negative and non-drinking (*P <* 0.05, respectively). Moreover, the risk were higher for those who were carriers *KAT2B* rs17006625 GG and were also HBsAg-negative (*P <* 0.05).

**CONCLUSION**: Of twelve cell cycle pathway genes, *MCM4*, *CHEK1* and *KAT2B* polymorphisms may be associated with the risk of HCC.

**Key words**: Cell cycle pathway genes; Single nucleotide polymorphism; Hepatocellular carcinoma; Genetic susceptibility; Case-control study

© **The Author (s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We analyzed the effects of twelve cell cycle pathway genes polymorphisms on the risk of hepatocellular carcinoma (HCC) in a large population of 1019 HCC cases and 1138 controls. The results suggest that *MCM4* rs2305952 CC and *CHEK1* rs515255 TC, TT, TC/TT may be significantly associated with a decreased risk of HCC. *KAT2B* rs17006625 GG may increase the risk of HCC.

Nan YL, Hu YL, Liu ZK, Duan FF, Xu Y, Li S, Li T, Chen DF, Zeng XY. Relationships between cell cycle pathway genes polymorphisms and the risk of hepatocellular carcinoma. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is a serious threat to human health worldwide. It is the fourth most common cancer and the second leading cause of cancer death, with nearly 746000 deaths per year[1]. The incidence of this fatal disease continues to increase. HCC occurrence and development is related to environmental factors, such as infection of hepatitis B virus (HBV) or hepatitis C virus (HCV), cigarette smoking, and alcohol consumption, as well as genetic susceptibility[2-4]. Many studies strongly support that single nucleotide polymorphisms (SNPs) of a variety of genes are associated with HCC[5-7]. However, the genetic mechanism underlying the inherited component of HCC is still not fully understood.

The cell cycle comprises the events that result in the formation of two daughter cells through division of the parent cell. Cell cycle progression, including cell division, is influenced by three different types of molecules: cyclin, cyclin-dependent kinases, and cyclin kinase inhibitors[8]. The associations between the genetic susceptibility of genes which regulate the cell cycle and the risk of cancer are well known. For instance, a polymorphism of the *p27* generates an increased risk of squamous cell carcinoma of the head and neck[9], while polymorphisms of *p27* and *p21* are associated with a significantly increased risk of HCC[10]. Other cell cycle pathway genes implicated in cancer include *cyclinD1*[11], *p53* [12], *CHEK2*[13] and *P21*[14].

During the last several decades, an increasing number of studies have shown an association between genetic variants, mainly in the form of single nucleotide polymorphisms (SNPs) and the risk of cancer, including breast[15] , colorectal[16], cervical, and vulvar cancers[17], and HCC[18]. Despite investigations into the association of polymorphisms in cell cycle pathway genes and cancer susceptibility[19,20], in the case of HCC this association remains unclear. Therefore, in this hospital-based study we investigated the association between the polymorphisms of SNPs in cell cycle pathway genes and the risk of HCC in 1127 HCC patients and 1200 controls from the Chinese population.

**MATERIALS AND METHODS**

***Study population***

For this case-control study, 2327 subjects were consecutively recruited from June 2007 to December 2013. The 1127 HCC patients were from the Tumor Hospital of Guangxi Medical University and were newly diagnosed with HCC based on biochemical (α-fetoprotein > 20 μg/L) and histopathological examinations. None had undergone radiotherapy or chemotherapy before blood sampling. The 1200 controls from the First Affiliated Hospital of Guangxi Medical University consisted of non-tumor patients admitted within the same period of time. Informed consent was obtained from all participants, who also agreed to truthful completion of the questionnaires.

***Information and sample collection***

General demographic and behavioral information, hematological indices, and data on the patients’ age, sex, nationality, drinking habit, smoking habit, HBV infection, and family history of HCC were obtained in face-to-face interviews by trained investigators. Peripheral venous blood was collected in a vacuum EDTA anticoagulant tube from each participant. Genomic DNA was extracted using a standard phenol-chloroform extraction method and stored at −80 oC.

***SNP selection***

From the GEO database (https://www.ncbi.nlm.nih.gov/geo/), we found three sets of whole genome expression microarray data which were related to HCC (GSE14520, GSE25097, GSE12941). 3826 different genes were selected using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) (*P <* 0.05). Gene ontology classification and pathway enrichment analysis were performed by blast2GO and DAVID (https://david.ncifcrf.gov/) and 40 cell cycle pathway genes involved in the cellular process were chose. Download the genotype data from Hapmap (http://hapmap.ncbi.nlm.nih.gov/), then performed Haploview 4.2 (Cambridge, MA o2141, USA) and function prediction website (http://snpinfo.niehs.nih.gov/snpfunc.htm) to selected functional SNPs (MAF > 0.05, r2 > 0.8). Through the reference to existing literature on these SNPs with HCC, fifteen SNPs in twelve genes (*MCM4* rs2305952，*YWHAB* rs2425675，*CDKN2A* rs3088440，*TGFB3* rs3917148，*RBL2* rs3929，*RAD21* rs6987652，*SMAD3* rs11556090, rs8025774，*KAT2B* rs17006625, rs4858770，*MCM7* rs2070215, rs2261360，*CDKN1A* rs3176320，*CDC25C* rs3734166，and *CHEK1* rs515255) were selected in this study. Information of selected SNPs is shown in Table 1.

***SNP genotyping***

Before genotyping, each DNA sample was quantified using a UV-Vis spectrophotometer Q5000 (Quawell Technology, Inc., USA) and diluted to a final concentration of 50 ng/μL. SNP genotyping was performed using a MassARRAY system (Sequenom, San Diego, CA, USA) and a matrix-assisted laser desorption ionization-time of flight mass spectrometry method according to the manufacturer’s instructions. Primers for PCR and extension were designed using the Assay Designer software package (Sequenom). For quality control, 5% of the samples were randomly chosen and genotyped twice for each locus. Among the 1127 patient samples and 1200 control samples, genotyping was successful for all 15 SNPs in both groups, with a success rate of 92.7%. Thus, all 1019 HCC patients and 1138 controls were included in the final analysis.

***Statistical analysis***

Statistical analyses were performed using the SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). Continuous variables differences were evaluated using the two-sample *t*-test. Categorical variables and genotype frequencies between the HCC patients and controls were compared using the Pearson’s χ2 and Fisher’s exact test. Hardy-Weinberg equilibrium (HWE) was evaluated by a goodness-of-fit χ2 test to compare the observed genotype frequencies with the expected ones. The association between SNP genotypes and HCC risk was estimated using unconditional logistic regression analysis and an odds ratio (OR) with 95% confidence interval (CI). All statistical tests were two-sided. A *P* value < 0.05 was considered to indicate statistical significance.

**RESULTS**

***Characteristics of the participants***

The 2157 unrelated Chinese subjects enrolled in this study included 881 (86.5%) males and 138 (13.5%) females with HCC. The mean age of these patients was 48.54 ± 11.44 years. The control group consisted of 982 (86.3%) males and 156 (13.7%) females, with a mean age of 48.01 ± 11.5 years. The general demographic characteristics and behavior information on the patients and controls are provided in Table 2. There were no significant differences between the HCC patients and the controls in terms of age, sex, and nationality; however, HCC patients had a significantly higher rate of a positive history of HBV infection, a family history of HCC, smoking, and drinking.

***Allele frequencies and genotype distribution***

In the control group, the genotype frequencies of the 15 SNPs, all but *CDKN1A* rs3176320 were in line with the HWE (*P* > 0.05), which indicated that these study participants were from a homogeneous group. The allele frequencies and genotype distribution of SNPs among the HCC patients and controls from this study are listed in Table 3.

***Association analysis of genetic polymorphisms and HCC***

The association between SNPs and the risk of HCC was examined using unconditional logistic regression analysis. According to the crude ORs and their 95%CIs, *SMAD3* rs11556090 AG or AG/GG and *MCM7* rs2070215 GG carried an increased risk of HCC when compared with the wild genotype *SMAD3* rs11556090 AA and *MCM7* rs2070215 AA, respectively. Individuals with *CDC25C* rs3734166 GG or GA/GG and *KAT2B* rs4858770 TT had a lower risk of HCC than those with the wild genotype *CDC25C* rs3734166 AA and *KAT2B* rs4858770 CC, respectively. However, the association disappeared after adjusting for age, sex, nationality, smoking, drinking, family history of HCC, and HBV infection. Using individuals with the wild genotype AA as the reference, individuals carrying the GG variant of *KAT2B* rs17006625 had a higher risk of HCC (adjusted OR = 1.64, 95%CI: 1.01–2.64, *P* = 0.04) after adjusting for confounding factors. In addition, compared with the wild genotypes *MCM4* rs2305952 TT and *CHEK1* rs515255 CC, individuals carrying the CC variant of *MCM4* rs2305952 or the TC, TT, TC/TT variants of *CHEK1* rs515255 had significantly lower risk of HCC (adjusted OR = 0.22, 95%CI: 0.08–0.63, *P* = 0.01; adjusted OR = 0.73, 95%CI: 0.56–0.96, *P* = 0.02; adjusted OR = 0.67, 95%CI: 0.46–0.97, *P* = 0.04; adjusted OR = 0.72, 95%CI: 0.56–0.92, *P* = 0.01, respectively). The associations are shown in Table 4.

***Association between SNPs and HCC risk stratified by behavioral factors***

HBV infection, alcohol intake status, and smoking status are important behavioral factors that can increase the risk of HCC. To account for the role of these factors, a stratified analysis was conducted. Thus, when the patients were stratified, we found that the variant genotype CC of *MCM4* rs2305952 was associated with a significantly lower risk of HCC among HBsAg-positive individuals, non-drinkers, and non-smokers (adjusted OR = 0.25, 95%CI: 0.08–0.80, *P* = 0.02; adjusted OR = 0.19, 95%CI: 0.06–0.60, *P* = 0.004; adjusted OR = 0.17, 95%CI: 0.05–0.56, *P* = 0.004, respectively). The variant genotypes TC, TT, and TC/TT of *CHEK1* rs515255 were associated with a significantly lower risk of HCC in HBsAg-negative individuals (adjusted OR = 0.64, 95%CI: 0.46–0.89, *P* = 0.01; adjusted OR = 0.69, 95%CI: 0.36–0.96, *P* = 0.03; adjusted OR = 0.63, 95%CI: 0.46–0.86, *P* = 0.003) and in non-drinkers (adjusted OR = 0.73, 95%CI: 0.54–0.99, *P* = 0.05; adjusted OR = 0.56, 95%CI: 0.36–0.86, *P* = 0.01; adjusted OR = 0.69, 95%CI: 0.52–0.92, *P* = 0.01, respectively). Among smokers, those with the TC variant genotype of *CHEK1* rs515255 had a significantly lower risk of HCC (adjusted OR = 0.54, 95%CI: 0.32–0.93, *P* = 0.03), while among non-smokers the risk was significantly lower in those with the TT variant genotype (adjusted OR = 0.60, 95%CI: 0.39–0.94, *P* = 0.03). In addition, the variant genotype GG of *KAT2B* rs17006625 was shown to carry a significantly higher risk of HCC among HBsAg-negative individuals (adjusted OR = 1.79, 95%CI: 1.02–3.12, *P* = 0.04). These findings are summarized in Tables 5–7 (only significant SNPs are shown).

**DISCUSSION**

We performed this case-control study to investigate the association between the fifteen SNPs in twelve cell cycle pathway genes and the risk of HCC. The *KAT2B* rs17006625 GG was associated with an increased risk of HCC. Furthermore, this harmful effect was more marked in those who were carriers with HBsAg-negative. Conversely, the *CHEK1* rs515255 TC, TT, TC/TT and the *MCM4* rs2305952 CC were associated with a decreased risk of HCC. In addition, the risk were markedly lower for those who were carriers of *MCM4* rs2305952 CC and were also HBsAg-positive and non-drinking and non-smoking and for those who were carriers of the TC, TT, TC/TT genotype of *CHEK1* rs515255 and were also HBsAg-negative and non-drinking. No significant associations were observed between other twelve SNPs polymorphisms and HCC risk.

The cell cycle pathway is one of the most important cellular signaling pathways, as it regulates both cell division and apoptosis. DNA damage readily leads to dysregulation of the cell cycle, which is an essential step in the initiation and development of human malignancies[21-23]. In the present study, we reported that three SNPs in cell cycle pathway genes (*MCM4*, *CHEK1*, and *KAT2B*) polymorphisms were significantly associated with the risk of HCC**.**

MCM4, a member of the mini-chromosome maintenance family of proteins, which interact with cell cycle checkpoints and recombinant proteins to stabilize the S phase, is essential for the initiation of eukaryotic genome replication[24,25]. Several reports have shown that MCM4 protein is overexpressed in patients with esophageal carcinomas[26], cervical cancer[27], and cervical squamous cell carcinoma[28]. In our study, we found that the polymorphism of *MCM4* rs2305952 was associated with lower risk of HCC. However, the mechanism of *MCM4* polymorphisms in HCC acceptance and development remains unclear. Ishimi *et al*[29] found thatMCM4 is one of the crucial targets of DNA replication checkpoint and the phoshporylation of MCM4, which is caused by the activation of ATR-CHK1 pathway and CDK2，result in the DNA replication through the inactivation of the MCM4/6/7 complex. It is also found that *MCM4* mutations may cause tumors by affecting the formation of the MCM4/6/7 complex[30,31].

*CHEK1* is a mediator of cell cycle arrest in response to DNA damage. In addition to controlling cell cycle progression[32], it regulates DNA repair[33] and coordinates cell survival and death[34,35]. It is reported that CHEK1 play an important role in the checkpoint of DNA damage and DNA replication through the ATR-CHK1 pathway[36-38]. Lin *et al*[39] performed a meta-analysis to explore the association of *CHEK1* SNPs with breast cancer in patients registered in the database of the Utah Breast Cancer Study. They found that *CHEK1* polymorphisms are significantly associated with the risk of breast cancer. However, in that study common alleles of *CHEK1* are not implicated in breast cancer risk or in the survival of breast cancer patients after meta-analysis. Our results showed an association between the *CHEK1* rs515255 genetic variant and a decreased risk of HCC, after adjusting for age, sex, nationality, smoking, drinking, family history of HCC, and HBV infection. The conflicting results may reflect the different cancers evaluated and/or differences in the study population. They remain to be clarified in further investigations.

*KAT2B*, also known as *PCAF*, encodes the cofactor PCAF (P300/CBP associated factor) of activated nucleoprotein that is important in cell cycle regulation. KAT2B induces cell cycle arrest and/or apoptosis by regulating p53 and affects the acetylation and stability of E2F1 in the presence of DNA damage[40,41]. Overexpression of PCAF was reported in samples of both central nervous system tumors and Wilm's tumors[42]. In addition, an association between *KAT2B* gene polymorphisms and several human diseases and behaviors has been reported. For example, the *KAT2B* SNP rs9829896 is associated with drug abuse in African Americans[43]. We also found that the risk of HCC was higher in individuals with the *KAT2B* rs17006625 GG genotype than with the AA genotype, after adjusting for age, sex, nationality, smoking, drinking, family history of HCC, and HBV infection.

HBV infection status, drinking status, and smoking status are well known to influence the occurrence and development of HCC[44-47]. Moreover, some genotypes have no effect on HCC risk when considered within a population as a whole, but the subgroup analysis may show an effect on HCC risk among alcohol drinkers and/or smokers[48,49]. Therefore, in our study, we evaluated the role of risk factors such as drinking status and smoking status in a stratified analysis and found that these environmental factors may be interacted with the analyzed SNPs.

Our study had several limitations. First, the research population was drawn only from the Guangxi Zhuang Autonomous Region. Whether the results apply to the Chinese population as a whole or to other ethnic groups remains to be seen. Second, because our study used a case-control format, recall bias was difficult to avoid. However, we sought to minimize recall bias by choosing patients newly diagnosed with HCC. Finally, the functional influence of the examined SNPs and the potential mechanisms need to be determined in functional validation tests.

In conclusion, *MCM4* rs2305952 CC and *CHEK1* rs515255 TC, TT, TC/TT may decrease the risk of HCC and *KAT2B* rs17006625 GG may increase the risk of HCC. In addition, we observed an increased risk associated with *KAT2B* rs17006625 GG in HBsAg-negative patients. Furthermore, we also observed a decreased risk associated with *MCM4* rs2305952 CC in HBsAg-positive patients and in also non-drinking patients and non-smoking patients, and with *CHEK1* rs515255 TC, TT, TC/TT in HBsAg-negative patients and in also non-drinking patients. Our results suggest that the genetic variants in the cell cycle pathway genes affect the risk of HCC, however, further studies are needed to clarify the findings.

**ACKNOWLEDGEMENTS**

We sincerely thank the staff of the First Affiliated Hospital of Guangxi Medical University and the Tumor Hospital of Guangxi Medical University for their support in recruiting the study participants. We also thank Dafang Chen and his students at the Peking University Health Science Center for technical help.

**COMMENTS**

***Background***

The uncontrollable proliferation of cancer cells is a crucial mechanism in cancer development and progression. Previous studies have shown that polymorphisms of cell cycle pathway genes are associated with cancer. However, their relationship with hepatocellular carcinoma (HCC) is unclear.

***Research frontiers***

Despite reports of an association between polymorphisms in cell cycle pathway genes and cancer risk, little is known about the relationship between these polymorphisms and HCC risk.

***Innovations and breakthroughs***

This study enrolled 1127 cases newly diagnosed with HCC and 1200 non-tumor patients. It comprehensively investigated the relationship between fifteen SNPs in twelve cell cycle pathway genes and HCC risk.

***Applications***

Since individuals with the *KAT2B* rs17006625 GG genotype may have an increased risk of HCC, they should be carefully monitored to reduce the occurrence and development of HCC.

***Terminology***

A single nucleotide polymorphism (SNP) is a variation in the genomic DNA sequence. SNPs in some genes may cause an increased or decreased risk of HCC.

***Peer-review***

The manuscript is interesting and providing relevant information. The study is a descriptive paper analyzing the polymorphism in HCC in a wide number of patients. The analyses are consistent with the results and the conclusions asserted in the manuscript.

**REFERENCES**

1 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]

2 **Franceschi S**, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, Casarin P, Izzo F, Tommasi LG, Chemin I, Trépo C, Crovatto M, Talamini R. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 683-689 [PMID: 16614109 DOI: 10.1158/1055-9965.EPI-05-0702]

3 **Dragani TA**. Risk of HCC: genetic heterogeneity and complex genetics. *J Hepatol* 2010; **52**: 252-257 [PMID: 20022654 DOI: 10.1016/j.jhep.2009.11.015]

4 **Kanda M**, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. *World J Gastroenterol* 2015; **21**: 10584-10597 [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584]

5 **Labib HA**, Ahmed HS, Shalaby SM, Wahab EA, Hamed EF. Genetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma. *Cell Immunol* 2015; **294**: 21-24 [PMID: 25666505 DOI: 10.1016/j.cellimm.2015.01.012]

6 **Liu F**, Luo LM, Wei YG, Li B, Wang WT, Wen TF, Yang JY, Xu MQ, Yan LN. Polymorphisms of the CYP1B1 gene and hepatocellular carcinoma risk in a Chinese population. *Gene* 2015; **564**: 14-20 [PMID: 25796598 DOI: 0.1016/j.gene.2015.03.035]

7 **Son MS**, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, Kim NK. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. *Gene* 2013; **524**: 156-160 [PMID: 23632240 DOI: 10.1016/j.gene.2013.04.042]

8 **Bretones G**, Delgado MD, León J. Myc and cell cycle control. *Biochim Biophys Acta* 2015; **1849**: 506-516 [PMID: 24704206 DOI: 10.1016/j.bbagrm.2014.03.013]

9 **Wang Z**, Sturgis EM, Zhang F, Lei D, Liu Z, Xu L, Song X, Wei Q, Li G. Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck. *Mol Cancer* 2012; **11**: 17 [PMID: 22449259 DOI: 10.1186/1476-4598-11-17]

10 **Liu F**, Wei YG, Luo LM, Wang WT, Yan LN, Wen TF, Xu MQ, Yang JY, Li B. Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case-control study. *Int J Cancer* 2013; **132**: 2056-2064 [PMID: 23034899 DOI: 10.1002/ijc.27885]

11 **Liao D**, Wu Y, Pu X, Chen H, Luo S, Li B, Ding C, Huang GL, He Z. Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a case-control study and meta-analysis. *PLoS One* 2014; **9**: e113299 [PMID: 25409185 DOI: 10.1371/journal.pone.0113299]

12 **Xue L**, Han X, Liu R, Wang Z, Li H, Chen Q, Zhang P, Wang Z, Chong T. MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer. *Oncotarget* 2015 May 18; Epub ahead of print [PMID: 26025918 DOI: 10.18632/oncotarget.3923]

13 **Banaszkiewicz M**, Constantinou M, Pietrusiński M, Kępczyński L, Jędrzejczyk A, Rożniecki M, Marks P, Kałużewski B. Concomitance of oncogenic HPV types, CHEK2 gene mutations, and CYP1B1 gene polymorphism as an increased risk factor for malignancy. *Cent European J Urol* 2013; **66**: 23-29 [PMID: 24578981 DOI: 10.5173/ceju.2013.01.art7]

14 **Wang N**, Wang S, Zhang Q, Lu Y, Wei H, Li W, Zhang S, Yin D, Ou Y. Association of p21 SNPs and risk of cervical cancer among Chinese women. *BMC Cancer* 2012; **12**: 589 [PMID: 23231583 DOI: 10.1186/1471-2407-12-589]

15 **Ullah Shah A**, Mahjabeen I, Kayani MA. Genetic polymorphisms in cell cycle regulatory genes CCND1 and CDK4 are associated with susceptibility to breast cancer. *J BUON* 2015; **20**: 985-993 [PMID: 26416047]

16 **Akbari Z**, Safari-Alighiarloo N, Taleghani MY, Mirfakhar FS, Asadzadeh Aghdaei H, Vahedi M, Irani Shemirani A, Nazemalhosseini-Mojarad E, Zali MR. Polymorphism of SMAD7 gene (rs2337104) and risk of colorectal cancer in an Iranian population: a case-control study. *Gastroenterol Hepatol Bed Bench* 2014; **7**: 198-205 [PMID: 25289133]

17 **Hardikar S**, Johnson LG, Malkki M, Petersdorf EW, Galloway DA, Schwartz SM, Madeleine MM. A population-based case-control study of genetic variation in cytokine genes associated with risk of cervical and vulvar cancers. *Gynecol Oncol* 2015; **139**: 90-96 [PMID: 26241630 DOI: 10.1016/j.ygyno.2015.07.110]

18 **Qiu M**, Liu Y, Yu X, Qin L, Bei C, Zeng X, Qiu X, Tang B, He S, Yu H. Interaction between p53 codon 72 and MDM2 309T& gt; G polymorphisms and the risk of hepatocellular carcinoma. *Tumour Biol* 2016; **37**: 3863-3870 [PMID: 26476535 DOI: 10.1007/s13277-015-4222-4]

19 **Murali A**, Nalinakumari KR, Thomas S, Kannan S. Association of single nucleotide polymorphisms in cell cycle regulatory genes with oral cancer susceptibility. *Br J Oral Maxillofac Surg* 2014; **52**: 652-658 [PMID: 24947332 DOI: 10.1016/j.bjoms.2014.05.010]

20 **Wang W**, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. *Clin Cancer Res* 2007; **13**: 5974-5981 [PMID: 17908995 DOI: 10.1158/1078-0432.CCR-07-0113]

21 **Fernández PL**, Jares P, Rey MJ, Campo E, Cardesa A. Cell cycle regulators and their abnormalities in breast cancer. *Mol Pathol* 1998; **51**: 305-309 [PMID: 10193510 DOI: 10.1136/mp.51.6.305]

22 **Park MT**, Lee SJ. Cell cycle and cancer. *J Biochem Mol Biol* 2003; **36**: 60-65 [PMID: 12542976]

23 **Todd R**, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y, Wong DT. Cell cycle dysregulation in oral cancer. *Crit Rev Oral Biol Med* 2002; **13**: 51-61 [PMID: 12097237 DOI: 10.1177/154411130201300106]

24 **Bailis JM**, Luche DD, Hunter T, Forsburg SL. Minichromosome maintenance proteins interact with checkpoint and recombination proteins to promote s-phase genome stability. *Mol Cell Biol* 2008; **28**: 1724-1738 [PMID: 18180284 DOI: 10.1128/MCB.01717-07]

25 **Yu Z**, Feng D, Liang C. Pairwise interactions of the six human MCM protein subunits. *J Mol Biol* 2004; **340**: 1197-1206 [PMID: 15236977 DOI: 10.1016/j.jmb.2004.05.024]

26 **Huang XP**, Zhang X, Su XD, Ma GW, Zhao JM, Rong TH. [Expression and significance of MCM4 in esophageal cancer]. *Ai Zheng* 2007; **26**: 96-99 [PMID: 17222376]

27 **Das M**, Prasad SB, Yadav SS, Govardhan HB, Pandey LK, Singh S, Pradhan S, Narayan G. Over expression of minichromosome maintenance genes is clinically correlated to cervical carcinogenesis. *PLoS One* 2013; **8**: e69607 [PMID: 23874974 DOI: 10.1371/journal.pone.0069607]

28 **Huber AR**, Tan D, Sun J, Dean D, Wu T, Zhou Z. High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7. *BMC Gastroenterol* 2015; **15**: 80 [PMID: 26156831 DOI: 10.1186/s12876-015-0310-6]

29 **Ishimi Y**, Komamura-Kohno Y, Kwon HJ, Yamada K, Nakanishi M. Identification of MCM4 as a target of the DNA replication block checkpoint system. *J Biol Chem* 2003; **278**: 24644-24650 [PMID: 12714602 DOI: 10.1074/jbc.M213252200]

30 **Shima N**, Buske TR, Schimenti JC. Genetic screen for chromosome instability in mice: Mcm4 and breast cancer. *Cell Cycle* 2007; **6**: 1135-1140 [PMID: 17495541]

31 **Watanabe E**, Ohara R, Ishimi Y. Effect of an MCM4 mutation that causes tumours in mouse on human MCM4/6/7 complex formation. *J Biochem* 2012; **152**: 191-198 [PMID: 22668557 DOI: 10.1093/jb/mvs060]

32 **Maya-Mendoza A**, Petermann E, Gillespie DA, Caldecott KW, Jackson DA. Chk1 regulates the density of active replication origins during the vertebrate S phase. *EMBO J* 2007; **26**: 2719-2731 [PMID: 17491592 DOI: 10.1038/sj.emboj.7601714]

33 **Sørensen CS**, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. *Nat Cell Biol* 2005; **7**: 195-201 [PMID: 15665856 DOI: 10.1038/ncb1212]

34 **Sahu RP**, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. *Br J Cancer* 2009; **100**: 1425-1433 [PMID: 19401701 DOI: 10.1038/sj.bjc.6605039]

35 **Smith J**, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. *Adv Cancer Res* 2010; **108**: 73-112 [PMID: 21034966 DOI: 10.1016/B978-0-12-380888-2.00003-0]

36 **Sørensen CS**, Syljuåsen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. *Nucleic Acids Res* 2012; **40**: 477-486 [PMID: 21937510 DOI: 10.1093/nar/gkr697]

37 **Reinhardt HC**, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. *Curr Opin Cell Biol* 2009; **21**: 245-255 [PMID: 19230643 DOI: 10.1016/j.ceb.2009.01.018]

38 **Seiler JA**, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. *Mol Cell Biol* 2007; **27**: 5806-5818 [PMID: 17515603 DOI: 10.1128/MCB.02278-06]

39 **Lin WY**, Brock IW, Connley D, Cramp H, Tucker R, Slate J, Reed MW, Balasubramanian SP, Cannon-Albright LA, Camp NJ, Cox A. Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer. *PLoS One* 2013; **8**: e68578 [PMID: 23844225 DOI: 10.1371/journal.pone.0068578]

40 **Liu L**, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, Berger SL. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. *Mol Cell Biol* 1999; **19**: 1202-1209 [PMID: 9891054 DOI: 10.1128/MCB.19.2.1202]

41 **Ianari A**, Gallo R, Palma M, Alesse E, Gulino A. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. *J Biol Chem* 2004; **279**: 30830-30835 [PMID: 15123636 DOI: 10.1074/jbc.M402403200]

42 **Armas-Pineda C**, Arenas-Huertero F, Pérezpeñia-Diazconti M, Chico-Ponce de León F, Sosa-Sáinz G, Lezama P, Recillas-Targa F. Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors. *J Exp Clin Cancer Res* 2007; **26**: 269-276 [PMID: 17725108]

43 . KAT2B polymorphism identified for drug abuse in African Americans with regulatory links to drug abuse pathways in human prefrontal cortex. *Addict Biol* 2015; : [PMID: 26202629 DOI: 10.1111/adb.12286]

44 **Marrero JA**, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. *J Hepatol* 2005; **42**: 218-224 [PMID: 15664247 DOI: 10.1016/j.jhep.2004.10.005]

45 **Tanaka M**, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. *J Epidemiol* 2011; **21**: 401-416 [PMID: 22041528 DOI: 10.2188/jea.JE20100190]

46 **Gambarin-Gelwan M**. Viral hepatitis, non-alcoholic fatty liver disease and alcohol as risk factors for hepatocellular carcinoma. *Chin Clin Oncol* 2013; **2**: 32 [PMID: 25841911 DOI: 10.3978/j.issn.2304-3865.2013.09.02]

47 **Lin H**, Ha NB, Ahmed A, Ayoub W, Daugherty TJ, Lutchman GA, Garcia G, Nguyen MH. Both HCV and HBV are major causes of liver cancer in Southeast Asians. *J Immigr Minor Health* 2013; **15**: 1023-1029 [PMID: 23864445 DOI: 10.1007/s10903-013-9871-z]

48 **Zhang J**, Xu F, Ouyang C. Joint effect of polymorphism in the N-acetyltransferase 2 gene and smoking on hepatocellular carcinoma. *Tumour Biol* 2012; **33**: 1059-1063 [PMID: 22293947 DOI: 10.1007/s13277-012-0340-4]

49 **Hsieh YH**, Chang WS, Tsai CW, Tsai JP, Hsu CM, Jeng LB, Bau DT. DNA double-strand break repair gene XRCC7 genotypes were associated with hepatocellular carcinoma risk in Taiwanese males and alcohol drinkers. *Tumour Biol* 2015; **36**: 4101-4106 [PMID: 25944161 DOI: 10.1007/s13277-014-2934-5]

**P-Reviewer:** Alwahaibi NY, Patial V, Servillo G **S-Editor:** Yu J **L-Editor:** **E-Editor:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 1 Summarized information of selected single nucleotide polymorphisms in cell cycle pathway genes** | | | | |
| **Genes** | **SNPs** | **Chromosome (position)** | **Allele** | **MAF（hapmap-HCB）** |
| *MCM4* | rs2305952 | 8 (47962049) | C/T | C = 0.18 |
| *YWHAB* | rs2425675 | 20 (44906293) | A/G | A = 0.20 |
| *CDKN2A* | rs3088440 | 9 (21968160) | A/G | A = 0.08 |
| *TGFB3* | rs3917148 | 14 (75980178) | A/C | C = 0.10 |
| *RBL2* | rs3929 | 16 (53490396) | C/G | C = 0.20 |
| *RAD21* | rs6987652 | 8 (116870042) | A/G | A = 0.12 |
| *SMAD3* | rs11556090 | 15 (67194045) | A/G | G = 0.09 |
| rs8025774 | 15 (67190938) | C/T | C = 0.45 |
| *KAT2B* | rs17006625 | 3 (20119604) | A/G | G = 0.14 |
| rs4858770 | 3 (20152931) | C/T | T = 0.47 |
| *MCM7* | rs2070215 | 7 (100099174) | A/G | G = 0.29 |
| rs2261360 | 7 (100095370) | A/C | A = 0.37 |
| *CDKN1A* | rs3176320 | 6 (36679011) | A/G | G = 0.17 |
| *CDC25C* | rs3734166 | 5 (138329634) | A/G | G = 0.38 |
| *CHEK1* | rs515255 | 11 (125627250) | C/T | T = 0.44 |
| MAF (minor allele frequency) was derived from HCB population in HapMap website (<http://hapmap.ncbi.nlm.nih.gov/>). SNPs: Single nucleotide polymorphisms. | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 2 General demographic characteristics and behavioral information among hepatocellular carcinoma patients and controls** | | | | | |
| **Variables** | **HCC patients** |  | **Controls** | ***t*/χ2** | ***P* value** |
| *n* = 1019 |  | *n* = 1138 |
| Age | 48.54 ± 11.44 |  | 48.01 ± 11.50 | -1.076 | 0.28 |
| Gender |  |  |  |  |  |
| Male | 881 |  | 982 | 0.013 | 0.91 |
| Female | 138 |  | 156 |  |  |
| Nationalities |  |  |  |  |  |
| Han | 673 |  | 708 | 3.591 | 0.17 |
| Zhuang | 332 |  | 410 |  |  |
| Others | 14 |  | 20 |  |  |
| Drinking |  |  |  |  |  |
| Yes | 345 |  | 145 | 136.527 | < 0.001 |
| No | 674 |  | 993 |  |  |
| Smoking |  |  |  |  |  |
| Yes | 355 |  | 158 | 130.222 | < 0.001 |
| No | 664 |  | 980 |  |  |
| Chronic HBV infection |  |  |  |  |  |
| Yes | 794 |  | 109 | 1031.687 | < 0.001 |
| No | 225 |  | 1029 |  |  |
| Family history of HCC |  |  |  |  |  |
| Yes | 80 |  | 2 | 86.597 | < 0.001 |
| No | 939 |  | 1136 |  |  |

HCC: Hepatocellular carcinoma.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 3 Allele frequencies and genotype distribution of single nucleotide polymorphisms** | | | | | | | | | | |
|  |  | **HCC patients** |  | **Control** | | |  | |  | |
| **SNPs** | **Genotype** | ***n* = 1019 (%)** | | |  | ***n* = 1138 (%)** | | **χ2** | | ***P* value of HWE** |
| rs2305952 | TT | 801 (78.61) | | |  | 883 (77.59) | |  | |  |
|  | TC | 209 (20.51) | | |  | 238 (20.91) | | 0.04 | | 0.83 |
|  | CC | 9 (0.88) | | |  | 17 (1.49) | |  | |  |
| rs2425675 | GG | 632 (62.02) | | |  | 724 (63.62) | |  | |  |
|  | AG | 348 (34.15) | | |  | 374 (32.86) | | 0.96 | | 0.33 |
|  | AA | 39 (3.83) | | |  | 40 (3.51) | |  | |  |
| rs3088440 | GG | 750 (73.60) | | |  | 813 (71.44) | |  | |  |
|  | GA | 249 (24.44) | | |  | 300 (26.36) | | 0.19 | | 0.66 |
|  | AA | 20 (1.96) | | |  | 25 (2.20) | |  | |  |
| rs3917148 | AA | 773 (75.86) | | |  | 882 (77.50) | |  | |  |
|  | CA | 233 (22.87) | | |  | 235 (20.65) | | 1.32 | | 0.25 |
|  | CC | 13 (1.28) | | |  | 21 (1.85) | |  | |  |
| rs3929 | GG | 619 (60.75) | | |  | 688 (60.46) | |  | |  |
|  | GC | 349 (34.25) | | |  | 395 (34.71) | | 0.03 | | 0.86 |
|  | CC | 51 (5.00) | | |  | 55 (4.83) | |  | |  |
| rs6987652 | GG | 743 (72.91) | | |  | 843 (74.08) | |  | |  |
|  | AG | 251 (24.63) | | |  | 270 (23.73) | | 0.38 | | 0.54 |
|  | AA | 25 (2.45) | | |  | 25 (2.20) | |  | |  |
| rs11556090 | AA | 622 (61.04) | | |  | 749 (65.82) | |  | |  |
|  | AG | 352 (34.54) | | |  | 346 (30.40) | | 0.15 | | 0.70 |
|  | GG | 45 (4.42) | | |  | 43 (3.78) | |  | |  |
| rs17006625 | AA | 526 (51.62) | | |  | 620 (54.48) | |  | |  |
|  | AG | 412 (40.43) | | |  | 446 (39.19) | | 0.48 | | 0.49 |
|  | GG | 81 (7.95) | | |  | 72 (6.33) | |  | |  |
| rs2070215 | AA | 465 (45.63) | | |  | 554 (48.68) | |  | |  |
|  | AG | 424 (41.61) | | |  | 480 (42.18) | | <0.01 | | 1 |
|  | GG | 130 (12.76) | | |  | 104 (9.14) | |  | |  |
| rs2261360 | CC | 460 (45.14) | | |  | 484 (42.53) | |  | |  |
|  | CA | 433 (42.49) | | |  | 497 (43.67) | | 2.61 | | 0.11 |
|  | AA | 126 (12.37) | | |  | 157 (13.80) | |  | |  |
| rs3176320 | AA | 579 (56.82) | | |  | 687 (60.37) | |  | |  |
|  | GA | 383 (37.59) | | |  | 377 (33.13) | | 5.05 | | 0.02 |
|  | GG | 57 (5.59) | | |  | 74 (6.50) | |  | |  |
| rs3734166 | AA | 421 (41.32) | | |  | 421 (36.99) | |  | |  |
|  | GA | 481 (47.20) | | |  | 539 (47.36) | | 0.06 | | 0.80 |
|  | GG | 117 (11.48) | | |  | 178 (15.64) | |  | |  |
| rs4858770 | CC | 445 (43.67) | | |  | 465 (40.86) | |  | |  |
|  | CT | 461 (45.24) | | |  | 515 (45.25) | | 0.65 | | 0.42 |
|  | TT | 113 (11.09) | | |  | 158 (13.88) | |  | |  |
| rs515255 | CC | 408 (40.04) | | |  | 411 (36.12) | |  | |  |
|  | TC | 469 (46.03) | | |  | 553 (48.59) | | 0.29 | | 0.59 |
|  | TT | 142 (13.94) | | |  | 174 (15.29) | |  | |  |
| rs8025774 | CC | 313 (30.72) | | |  | 335 (29.44) | |  | |  |
|  | CT | 514 (50.44) | | |  | 547 (48.07) | | 1.32 | | 0.25 |
|  | TT | 192 (18.84) | | |  | 256 (22.50) | |  | |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 4 Associations between polymorphisms of single nucleotide polymorphisms with the risk of hepatocellular carcinoma** | | | | | | |
| **SNPs** | **Genotype** | **OR (95%CI)1** | ***P*1 value** |  | **OR (95%CI)2** | ***P*2 value** |
| rs2305952 | TT | reference |  |  | reference |  |
|  | TC | 0.97 (0.79-1.19) | 0.76 |  | 0.97 (0.72-1.32) | 0.85 |
|  | CC | 0.58 (0.26-1.32) | 0.19 |  | 0.22 (0.08-0.63) | 0.01a |
|  | TC/CC | 0.94 (0.77-1.16) | 0.57 |  | 0.89 (0.66-1.19) | 0.43 |
| rs2425675 | GG | reference |  |  | reference |  |
|  | AG | 1.07 (0.89-1.28) | 0.49 |  | 1.92 (0.71-1.20) | 0.54 |
|  | AA | 1.12 (0.71-1.76) | 0.63 |  | 0.97 (0.51-1.85) | 0.93 |
|  | AG/AA | 1.07 (0.90-1.28) | 0.44 |  | 0.93 (0.72-1.20) | 0.56 |
| rs3088440 | GG | reference |  |  | reference |  |
|  | GA | 0.90 (0.74-1.09) | 0.29 |  | 1.02 (0.76-1.35) | 0.92 |
|  | AA | 0.87 (0.48-1.58) | 0.64 |  | 1.46 (0.62-3.44) | 0.38 |
|  | GA/AA | 0.90 (0.74-1.09) | 0.26 |  | 1.04 (0.79-1.37) | 0.77 |
| rs3917148 | AA | reference |  |  | reference |  |
|  | CA | 1.13 (0.92-1.39) | 0.24 |  | 1.18 (0.88-1.59) | 0.28 |
|  | CC | 0.71 (0.35-1.42) | 0.33 |  | 1.05 (0.41-2.68) | 0.92 |
|  | CA/CC | 1.10 (0.90-1.34) | 0.37 |  | 1.17 (0.88-1.56) | 0.29 |
| rs3929 | GG | reference |  |  | reference |  |
|  | GC | 0.98 (0.82-1.18) | 0.84 |  | 0.97 (0.75-1.26) | 0.82 |
|  | CC | 1.03 (0.69-1.53) | 0.88 |  | 1.39 (0.80-2.42) | 0.25 |
|  | GC/CC | 0.99 (0.83-1.18) | 0.89 |  | 1.02 (0.79-1.30) | 0.90 |
| rs6987652 | GG | reference |  |  | reference |  |
|  | AG | 1.06 (0.87-1.29) | 0.6 |  | 0.92 (0.69-1.23) | 0.59 |
|  | AA | 1.14 (0.65-1.99) | 0.66 |  | 1.26 (0.55-2.88) | 0.59 |
|  | AG/AA | 1.06 (0.88-1.29) | 0.54 |  | 0.95 (0.72-1.25) | 0.71 |
| rs11556090 | AA | reference |  |  | reference |  |
|  | AG | 1.23 (1.02-1.47) | 0.03 |  | 1.11 (0.85-1.44) | 0.44 |
|  | GG | 1.26 (0.82-1.94) | 0.29 |  | 1.02 (0.54-1.91) | 0.96 |
|  | AG/GG | 1.23 (1.03-1.47) | 0.02 |  | 1.10 (0.85-1.42) | 0.47 |
| rs17006625 | AA | reference |  |  | reference |  |
|  | AG | 1.09 (0.91-1.30) | 0.35 |  | 1.07 (0.83-1.38) | 0.61 |
|  | GG | 1.33 (0.95-1.86) | 0.10 |  | 1.64 (1.01-2.64) | 0.04 a |
|  | AG/GG | 1.12 (0.95-1.33) | 0.18 |  | 1.14 (0.89-1.46) | 0.29 |
| rs2070215 | AA | reference |  |  | reference |  |
|  | AG | 1.05 (0.88-1.26) | 0.58 |  | 0.95 (0.73-1.24) | 0.71 |
|  | GG | 1.49 (1.12-1.98) | 0.01 |  | 1.39 (0.93-2.08) | 0.11 |
|  | AG/GG | 1.13 (0.95-1.34) | 0.16 |  | 1.03 (0.81-1.32) | 0.81 |
| rs2261360 | CC | reference |  |  | reference |  |
|  | CA | 0.92 (0.77-1.10) | 0.35 |  | 0.84 (0.64-1.09) | 0.19 |
|  | AA | 0.84 (0.65-1.10) | 0.21 |  | 0.89 (0.60-1.31) | 0.55 |
|  | CA/AA | 0.90 (0.76-1.07) | 0.22 |  | 0.85 (0.66-1.09) | 0.19 |
| rs3734166 | AA | reference |  |  | reference |  |
|  | GA | 0.89 (0.74-1.07) | 0.22 |  | 0.92 (0.71-1.21) | 0.56 |
|  | GG | 0.66 (0.50-0.86) | 0.002 |  | 0.86 (0.59-1.25) | 0.43 |
|  | GA/GG | 0.83 (0.70-0.99) | 0.04 |  | 0.91 (0.71-1.17) | 0.45 |
| rs4858770 | CC | reference |  |  | reference |  |
|  | CT | 0.94 (0.78-1.12) | 0.47 |  | 0.96 (0.74-1.24) | 0.74 |
|  | TT | 0.75 (0.57-0.98) | 0.04 |  | 0.80 (0.54-1.20) | 0.28 |
|  | CT/TT | 0.89 (0.75-1.06) | 0.19 |  | 0.92 (0.72-1.18) | 0.51 |
| rs515255 | CC | reference |  |  | reference |  |
|  | TC | 0.85 (0.71-1.03) | 0.09 |  | 0.73 (0.56-0.96) | 0.02 a |
|  | TT | 0.82 (0.63-1.07) | 0.14 |  | 0.67 (0.46-0.97) | 0.04 a |
|  | TC/TT | 0.85 (0.71-1.01) | 0.06 |  | 0.72 (0.56-0.92) | 0.01 a |
| rs8025774 | CC | reference |  |  | reference |  |
|  | CT | 1.01 (0.83-1.22) | 0.95 |  | 0.95 (0.72-1.27) | 0.74 |
|  | TT | 0.80 (0.63-1.02) | 0.08 |  | 0.94 (0.66-1.32) | 0.71 |
|  | CT/TT | 0.94 (0.78-1.13) | 0.52 |  | 0.95 (0.73-1.24) | 0.69 |
| 1OR and 95%CI without adjusting for confounding factors; 2OR and 95%CI with adjusting for age, sex, nationality, smoking, drinking, family history of hepatocellular carcinoma, and HBV infection. a*P <* 0.05 was considered statistically significant. OR: Odds ratio; CI: confidence interval; SNPs: Single nucleotide polymorphisms. | | | | | | |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 5 Stratified analysis on the association between single nucleotide polymorphisms’ genotype and hepatocellular carcinoma risk according to hepatitis B virus infection status** | | | | | | | | | |
| **SNPs** | **HBsAg-positive** | | | |  | **HBsAg-negative** | | | |
|  | **Case** | **Control** | **OR (95%CI)1** | ***P*1 value** |  | **Case** | **Control** | **OR (95%CI)1** | ***P*1 value** |
| rs2305952 |  |  |  |  |  |  |  |  |  |
| TT | 624 | 80 | reference |  |  | 177 | 803 | reference |  |
| TC | 161 | 24 | 0.86 (0.53-1.42) | 0.56 |  | 48 | 214 | 1.05 (0.72-1.52) | 0.80 |
| CC | 9 | 5 | 0.25 (0.08-0.80) | 0.02a |  | 0 | 12 | -- | 1 |
| TC/CC | 170 | 29 | 0.76 (0.48-1.21) | 0.25 |  | 48 | 226 | 0.99 (0.68-1.43) | 0.95 |
| rs17006625 |  |  |  |  |  |  |  |  |  |
| AA | 411 | 60 | reference |  |  | 115 | 560 | reference |  |
| AG | 323 | 42 | 1.15 (0.75-1.76) | 0.54 |  | 89 | 404 | 1.07 (0.77-1.48) | 0.68 |
| GG | 60 | 7 | 1.36 (0.59-3.17) | 0.47 |  | 21 | 65 | 1.79 (1.02-3.12) | 0.04a |
| AG/GG | 383 | 49 | 1.18 (0.78-1.77) | 0.44 |  | 110 | 469 | 1.17 (0.86-1.59) | 0.32 |
| rs515255 |  |  |  |  |  |  |  |  |  |
| CC | 301 | 39 | reference |  |  | 107 | 372 | reference |  |
| TC | 377 | 52 | 0.93 (0.59-1.46) | 0.75 |  | 92 | 501 | 0.64 (0.46-0.89) | 0.01 a |
| TT | 116 | 18 | 0.81 (0.44-1.50) | 0.51 |  | 26 | 156 | 0.69 (0.36-0.96) | 0.03 a |
| TC/TT | 493 | 70 | 0.90 (0.59-1.37) | 0.62 |  | 118 | 657 | 0.63 (0.46-0.86) | 0.003 a |
| 1OR and 95%CI with adjusting for age, sex, nationality, smoking, drinking and family history of hepatocellular carcinoma. a*P <* 0.05 was considered statistically significant. OR: Odds ratio; CI: Confidence interval. SNPs: Single nucleotide polymorphisms. | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | | | |
| **Table 6 Stratified analysis on the association between single nucleotide polymorphisms’ genotype and hepatocellular carcinoma risk according to drinking status** | | | | | | | | | |
| **SNPs** | **Drinking** | | | |  | **Non-drinking** | | | |
|  | Case | Control | OR (95%CI)1 | *P*1 value |  | Case | Control | OR (95%CI)1 | *P*1value |
| rs2305952 |  |  |  |  |  |  |  |  |  |
| TT | 273 | 111 | reference |  |  | 528 | 772 | reference |  |
| TC | 69 | 33 | 0.82 (0.44-1.52) | 0.53 |  | 140 | 205 | 1.02 (0.72-1.44) | 0.93 |
| CC | 3 | 1 | 0.51 (0.03-9.74) | 0.66 |  | 6 | 16 | 0.19 (0.06-0.60) | 0.004a |
| TC/CC | 72 | 34 | 0.81 (0.44-1.49) | 0.49 |  | 146 | 221 | 0.91 (0.65-1.27) | 0.57 |
| rs515255 |  |  |  |  |  |  |  |  |  |
| CC | 145 | 56 | reference |  |  | 263 | 355 | reference |  |
| TC | 154 | 71 | 0.69 (0.40-1.19) | 0.18 |  | 315 | 482 | 0.73 (0.54-0.99) | 0.05a |
| TT | 46 | 18 | 1.10 (0.50-2.43) | 0.82 |  | 96 | 156 | 0.56 (0.36-0.86) | 0.01a |
| TC/TT | 200 | 89 | 0.77 (0.46-1.29) | 0.31 |  | 411 | 638 | 0.69 (0.52-0.92) | 0.01a |
| 1OR and 95%CI with adjusting for age, sex, nationality, smoking, family history of hepatocellular carcinoma, and hepatitis B virus infection. a*P <* 0.05 was considered statistically significant. OR: Odds ratio; CI: Confidence interval; SNPs: Single nucleotide polymorphisms. | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | | | | | |
| **Table 7 Stratified analysis on the association between single nucleotide polymorphisms’ genotype and hepatocellular carcinoma risk according to smoking status** | | | | | | | | | | | |
| **SNPs** | **Smoking** | | | | | |  | **Non-smoking** | | | |
| Case | | Control | | OR (95%CI)1 | *P*1 value |  | Case | Control | OR (95%CI)1 | *P*1value |
| rs2305952 | | | |  |  |  |  |  |  |  |  |
| TT | | 274 | | 124 | reference |  |  | 527 | 759 | reference |  |
| TC | | 77 | | 32 | 1.05 (0.58-1.91) | 0.87 |  | 132 | 206 | 0.94 (0.66-1.34) | 0.75 |
| CC | | 4 | | 2 | 0.54 (0.06-4.97) | 0.59 |  | 5 | 15 | 0.17 (0.05-0.56) | 0.004 a |
| TC/CC | | 81 | | 34 | 1.01 (0.57-1.82) | 0.96 |  | 137 | 221 | 0.84 (0.60-1.19) | 0.33 |
| rs515255 | |  | |  |  |  |  |  |  |  |  |
| CC | | 145 | | 53 | reference |  |  | 263 | 358 | reference |  |
| TC | | 155 | | 84 | 0.54 (0.32-0.93) | 0.03 a |  | 314 | 469 | 0.81 (0.59-1.10) | 0.17 |
| TT | | 55 | | 21 | 0.87 (0.41-1.85) | 0.72 |  | 87 | 153 | 0.60 (0.39-0.94) | 0.03 a |
| TC/TT | | 210 | | 105 | 0.61 (0.67-1.02) | 0.06 |  | 401 | 622 | 0.75 (0.56-1.01) | 0.06 |
| 1OR and 95%CI with adjusting for age, sex, nationality, drinking, family history of hepatocellular carcinoma, and HBV infection. a*P <* 0.05 was considered statistically significant. OR: Odds ratio; CI: Confidence interval; SNPs: Single nucleotide polymorphisms. | | | | | | | | | | | |